Actuate Therapeutics
Market cap $15.2M 60.4M shares (10-Q, Nov 13, 2026) × $0.252 close Nov 17, 2026
Most recent annual filing: 2026-01-15
- Elraglusib Ph3 start2H 2026Elraglusib Ph3 start, 2H 2026, routine
- Elraglusib Oral Tablet Ph1 start2H 2026Elraglusib Oral Tablet Ph1 start, 2H 2026, routine
- corporate listing updateJan 11, 2027corporate listing update, Jan 11, 2027, routine
- Nasdaq listing - MVLS testJan 11, 2027Nasdaq listing - MVLS test, Jan 11, 2027, routine
- Nasdaq listing - bid priceApr 26, 2027Nasdaq listing - bid price, Apr 26, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
Elraglusib Oral Tablet
elraglusib · 9-ING-41- Undisclosed indication
elraglusib
Capital (as filed)
- Cash
- $2.1M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$3.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $13.9M cash per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure
Offering documents (2)
- 2026-10-28 424B5 · Priced offering 31.0M shares · at $0.71 · $11.0M gross · 77.5% above the prior close ($0.40, Oct 27, 2026)
- 2026-10-08 FWP · Pricing term sheet
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (18)
- 2026-11-14 UPDATE: Actuate Therapeutics (ACTU) - Underwater on Its Own Deal
- 2026-10-28 UPDATE: Actuate Therapeutics (ACTU) - Priced at 35.5 Cents
- 2026-10-20 UPDATE: Actuate Therapeutics (ACTU) - Half the Shares, Half the Cash, Plus Warrants 🔒 Paid
- 2026-10-15 UPDATE: Actuate Therapeutics (ACTU) - The Deal Is Chasing the Stock Down 🔒 Paid
- 2026-10-07 UPDATE: Actuate Therapeutics (ACTU) - The Dilution Finally Arrives
- 2026-09-10 UPDATE: Actuate Therapeutics (ACTU) - The Revolution Medicines Audition 🔒 Paid
- 2026-08-15 UPDATE: Actuate Therapeutics (ACTU) - $4.4 Million and Six Weeks 🔒 Paid
- 2026-07-17 UPDATE: Actuate Therapeutics (ACTU) - The Second Clock Just Started
- 2026-06-09 UPDATE: Actuate Therapeutics (ACTU) - Someone Else Is Paying for the Neuroblastoma Trial 🔒 Paid
- 2026-06-01 UPDATE: Actuate Therapeutics (ACTU) - The KRAS Wild-Type Tell 🔒 Paid
- 2026-05-12 UPDATE: Actuate Therapeutics (ACTU) - The Mersana Guy Just Joined the Board 🔒 Paid
- 2026-04-27 UPDATE: Actuate Therapeutics (ACTU) - Nature Medicine Blesses the Sledgehammer 🔒 Paid
- 2026-03-29 UPDATE: Actuate Therapeutics (ACTU) - The "Going Concern" Ghost and the July 2026 Cliff 🔒 Paid
- 2026-03-15 UPDATE: Actuate Therapeutics (ACTU) - A Great Science Project Doesn't Pay the Bills 🔒 Paid
- 2026-01-25 Update : Actuate Therapeutics (ACTU) Goes Oral - A Lazarus Patient, A Pill, and An Empty Checkbook 🔒 Paid
- 2026-01-13 UPDATE : Actuate Therapeutics (ACTU) Post-ASCO: The "Tail" Looks Real, but Is the Market is Blind? 🔒 Paid
- 2026-01-12 UPDATE: Actuate Therapeutics (ACTU) — Finding Green Shoots in the Graveyard 🔒 Paid
- 2026-01-07 Actuate Therapeutics (ACTU): Scientific Deep Dive for Elraglusib 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (18 calls)
Every verdict Biotech Distilled has published on Actuate Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-07 Avoid Actuate Therapeutics (ACTU): Scientific Deep Dive for Elraglusib Financing overhang from $100M ATM, commercially inferior efficacy vs NALIRIFOX, and a potentially false-positive Phase 2 driven by a weak control arm make this uninvestable for new buyers.
- 2026-01-12 Hold UPDATE: Actuate Therapeutics (ACTU) — Finding Green Shoots in the Graveyard Pediatric PRV optionality adds a tangible floor value, but the business remains broken; the scientific probability of success rose while the financing overhang persists.
- 2026-01-13 Avoid UPDATE : Actuate Therapeutics (ACTU) Post-ASCO: The "Tail" Looks Real, but Is the Market is Blind? Strong 24-month survival tail validates the science, but the financing overhang from the ATM is what the market is pricing and new buyers should wait for a secondary offering or partnership announcement.
- 2026-01-25 Avoid Update : Actuate Therapeutics (ACTU) Goes Oral - A Lazarus Patient, A Pill, and An Empty Checkbook The oral melanoma announcement broadens the narrative but does nothing to solve the solvency challenge; the $100M ATM dilution overhang remains the dominant factor.
- 2026-03-15 Avoid UPDATE: Actuate Therapeutics (ACTU) - A Great Science Project Doesn't Pay the Bills Preclinical RAS combination initiative is scientifically sound but does not fund a registrational trial; the dilution gap remains unsolved and the press release is window dressing on a burning building.
- 2026-03-29 Avoid UPDATE: Actuate Therapeutics (ACTU) - The "Going Concern" Ghost and the July 2026 Cliff Annual report formalizes going-concern doubt with a July 2026 cash expiry and $100M ATM locked and loaded; a great molecule trapped inside a broken balance sheet is a recipe for heavy losses.
- 2026-04-27 Hold UPDATE: Actuate Therapeutics (ACTU) - Nature Medicine Blesses the Sledgehammer Nature Medicine peer-reviewed validation materially weakens the weak-control-arm bear case and raises partnership probability, but the July 2026 cash cliff is unchanged so a full buy is not warranted.
- 2026-05-12 Watch UPDATE: Actuate Therapeutics (ACTU) - The Mersana Guy Just Joined the Board Huber's M&A pedigree and the oral IND clearance strengthen the BD/partnership narrative, but the balance sheet is still broken and a dip entry is needed before opening a position.
- 2026-06-01 Watch UPDATE: Actuate Therapeutics (ACTU) - The KRAS Wild-Type Tell KRAS WT subgroup with p<0.001 and FOLFIRINOX-backbone signal sharpen the BD pitch, but with only 8 weeks to the July cash cliff and no partnership announced, the market is pricing in the ATM.
- 2026-06-09 Watch UPDATE: Actuate Therapeutics (ACTU) - Someone Else Is Paying for the Neuroblastoma Trial Cancer Research UK funding the BEACON2 neuroblastoma trial adds capital-efficient PRV optionality, but the pancreatic/financing binary is unchanged with roughly 6 weeks to the July cash cliff.
- 2026-07-17 Avoid UPDATE: Actuate Therapeutics (ACTU) - The Second Clock Just Started Nasdaq MVLS deficiency notice adds a second independent deadline sharing the same cure as the cash cliff, shifting counterparty leverage further toward buyers and worsening the risk-adjusted odds.
- 2026-08-15 Avoid UPDATE: Actuate Therapeutics (ACTU) - $4.4 Million and Six Weeks Q2 10-Q reveals $4.4M cash and a September runway with no partnership signed; the risk profile has moved from binary toward genuinely distressed and waiting for the financing to clear is the better-compensated approach.
- 2026-09-10 Avoid UPDATE: Actuate Therapeutics (ACTU) - The Revolution Medicines Audition Preclinical synergy with two RAS(ON) inhibitors is the sharpest BD pitch the asset has ever had, but it is dish-and-mouse data with no p-values and the equity still faces an imminent financing event that hasn't been priced.
- 2026-10-07 Avoid UPDATE: Actuate Therapeutics (ACTU) - The Dilution Finally Arrives The 50M-share S-1 at ~$0.82 triples the share count and funds survival not a Phase 3; buying ahead of an unpriced float-tripling deal means taking dilution risk without the offering discount.
- 2026-10-15 Avoid UPDATE: Actuate Therapeutics (ACTU) - The Deal Is Chasing the Stock Down Amendment No. 1 upsizes to 65M shares at a lower assumed price that is already 33% above market, net proceeds could come in well under assumption, and the Nasdaq math no longer cures on the new count.
- 2026-10-20 Avoid UPDATE: Actuate Therapeutics (ACTU) - Half the Shares, Half the Cash, Plus Warrants Amendment No. 2 cuts to 40M shares with warrant sweetener raising only ~$18M net — roughly one year of survival — while adding a 25M+ warrant supply ceiling and leaving the Phase 3 unfunded.
- 2026-10-28 Avoid UPDATE: Actuate Therapeutics (ACTU) - Priced at 35.5 Cents Final pricing at $0.355/share raised only ~$11M gross — about two quarters of runway — with a $0.45 warrant ceiling just above the stock and the Phase 3 still unfunded; the terms make the case for staying on the sidelines.
- 2026-11-14 Avoid UPDATE: Actuate Therapeutics (ACTU) - Underwater on Its Own Deal Q3 10-Q shows $2.1M pre-raise cash and negative equity; post-raise going-concern language persists, a reverse split is now formally on management's option list, and the stock trades below the 35.5-cent deal price.
- Avoid call · opened Jan 7, 2026 at $6.49 · closed May 12, 2026 (downgraded to WATCH from avoid) at $2.89 · -55.5% vs XBI +6.7%
- Avoid call · opened Jul 20, 2026 at $1.40 · -82.0% vs XBI -3.7% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We look forward to further maturing this data, with additional updates expected in mid-2026.”
matched to Elraglusib · regulatory submission
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (27)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 13, 202610-QQuarterly report→ BD updateThe Q3 10-Q lands with cash at $2.1M pre-offering, the over-allotment fully exercised today for an additional $1.53M, total net proceeds of $11.76M — and a second Nasdaq compliance clock (minimum bid price, deadline April 26, 2027) now running alongside the MVLS deficiency.
- Nov 4, 2026ReleaseACTUATE THERAPEUTICS TO PRESENT PROMISING PRECLINICAL DATA DEMONSTRATING ANTITUMOR AND IMMUNE ACTIVATION ACTIVITY OF ELRAGLUSIB ORAL TABLET IN ADVANCED MELANOMA MODELS AT ENA 2026
- Nov 2, 2026ReleaseACTUATE THERAPEUTICS RECEIVES U.S. NOTICE OF ALLOWANCE FOR PATENT COVERING ELRAGLUSIB ORAL TABLETS
- Oct 30, 20268-KCurrent report: listing notice
- Oct 28, 20268-KCurrent report: material agreement, other events · EX-99.1 PRESS RELEASE DATED OCTOBER 27, 2026
- Oct 28, 2026424B5Prospectus supplement (offering)
- Oct 27, 2026ReleaseACTUATE THERAPEUTICS ANNOUNCES PRICING OF $11.0 MILLION UNDERWRITTEN PUBLIC OFFERING→ BD updateThe offering finally priced at $0.71/unit — smaller than every prior assumption, with warrants struck at $0.45 that are immediately in-the-money, netting the company roughly $10M to fund a runway measured in quarters, not years.
- Oct 19, 2026S-1/ARegistration statement (amended)→ BD updateThe offering that was chasing the stock down has been restructured a second time: units with warrants replace the straight equity deal, the assumed price resets to $0.50/share, and the post-offering diluted count shrinks — but the warrant overhang balloons. Here's what actually changed and what it means for the equity.
- Oct 14, 2026S-1/ARegistration statement (amended)→ BD updateThe offering that was supposed to save Actuate just got bigger and cheaper: the S-1/A upsizes to 65M shares at $0.64, down from 50M shares at $0.82, pushing the post-deal share count toward 89M and the stock to new lows near $0.43.
- Oct 8, 2026FWPFree writing prospectus (offering terms)
- Oct 6, 2026S-1Registration statement→ BD updateActuate finally pulled the trigger on the dilutive financing I've been warning about since November 2025 — a 50M-share S-1 at ~$0.82/share that more than triples the share count but buys real runway, kills the going-concern clock, and may cure the Nasdaq MVLS deficiency. The sledgehammer survives; the cap table gets hammered.
- Sep 9, 2026ReleaseActuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib→ BD updatePreclinical data from Northwestern and Mayo Clinic shows elraglusib synergizes with both zoldonrasib and daraxonrasib — the first FDA-approved broad RAS inhibitor — in FOLFIRINOX-resistant pancreatic cancer models, sharpening the BD pitch to Revolution Medicines and the RAS-pathway cohort just as the cash runway quietly extended to October 2026.
- Sep 9, 2026ReleaseActuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference→ BD updateSummary on the release
- Aug 14, 202610-QQuarterly report
- Jul 17, 20268-KCurrent report: listing notice
- Jun 9, 2026ReleaseACTUATE THERAPEUTICS’ ELRAGLUSIB SELECTED FOR EVALUATION IN BEACON2 TRIAL FOR HIGH-RISK PEDIATRIC NEUROBLASTOMABD extracted 1 program update from this document → ACTU pipeline
- Jun 1, 2026ReleaseACTUATE THERAPEUTICS ANNOUNCES ASCO POSTER PRESENTATIONS DEMONSTRATING COMPELLING CLINICAL AND BIOMARKER DATA FOR ELRAGLUSIB IN FIRST-LINE METASTATIC PANCREATIC CANCERBD extracted 1 program update from this document → ACTU pipeline
- May 22, 20268-KCurrent report: shareholder vote
- May 14, 202610-QQuarterly report
- May 11, 2026ReleaseACTUATE THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND FOR ORAL ELRAGLUSIB AND STRATEGIC INITIATIVES TO ADVANCE THE ELRAGLUSIB DEVELOPMENT PROGRAM
- May 11, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE
- May 6, 2026ReleaseACTUATE THERAPEUTICS ANNOUNCES KEY APPOINTMENT OF INDUSTRY VETERAN TO BOARD OF DIRECTORS
- May 6, 2026DEFA14AProxy soliciting material
- May 6, 20268-KCurrent report: officer / director change, other events · EX-99.1 PRESS RELEASE
- Apr 6, 2026DEFA14AProxy soliciting material
- Apr 6, 2026DEF 14AProxy statement
- Mar 26, 202610-KAnnual report
6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Oct 30, 2026SCHEDULE 13GPassive >5% holder (13G)
- Oct 26, 2026EFFECTRegistration effective
- Jun 8, 2026DRSDRS
- May 14, 2026S-8Employee plan registration
- Apr 22, 2026SCHEDULE 13G/A13G amendment
- Apr 9, 2026ARSAnnual report to shareholders